**2.2 Cancer-related risk factors are delineated based on malignancy site, stage, histopathology, and time after diagnosis**


Peritoneal surface malignancy (PSM) can be a manifestation of cancer metastasis from colorectal or ovarian malignant sites. Although, new methods of treatment such as cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPECH) can improve survival, these procedures are related to activating of coagulation cascade. Postoperative venous thromboembolism risk in PSM patients is as high as 30-50% without thrombo prophylaxis.

